The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
Vlastos, G.; Mirza, N. Q.; Lenert, J. T.; Hunt, K. K.; Ames, F. C.; Feig, B. W.; Ross, M. I.; Buzdar, A. U., and Singletary, S. E.. Cancer. 88(6):1417-1424, 2000 Mar 15.

Positron emission tomography using [F-18]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
Smith, I. C.; Welch, A. E.; Hutcheon, A. W.; Miller, I. D.; Payne, S.; Chilcott, F.; Waikar, S.; Whitaker, T.; Ah-See, A. K.; Eremin, O.; Heys, S. D.; Gilbert, F. J., and Sharp, P. F. Journal of Clinical Oncology. 18(8):1676-1688, 2000 Apr.

Preoperative paclitaxel and radiotherapy for locally advanced breast cancer: Surgical aspects.
Skinner, K. A.; Silberman, H.; Florentine, B.; Lomis, T. J.; Corso, F.; Spicer, D., and Formenti, S. C.. Annals of Surgical Oncology. 7(2):145-149, 2000 Mar.

High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients:
Does impact on quality of life jeopardize feasibility and acceptability of treatment? Macquart-Moulin, G.; Viens, P.; Palangie, T.; Bouscary, M. L.; Delozier, T.; Roche, H.; Janvier, M.; Fabbro, M., and Moatti, J. P. Journal of Clinical Oncology. 18(4):754-764, 2000 Feb.

Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients.
Lenert, J. T.; Vlastos, G.; Mirza, N. Q.; Winchester, D. J.; Binkley, S. M.; Ames, F. C.; Ross, M. I.; Feig, B. W.; Hunt, K. K.; Strom, E.; Buzdar, A. U.; Hortobagyi, G. N., and Singletary, S. E. Annals of Surgical Oncology. 6(8):762-767, 1999 Dec.

Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
Hoff, P. M.; Valero, V.; Buzdar, A. U.; Singletary, S. E.; Theriault, R. L.; Booser, D.; Asmar, L.; Frye, D.; McNeese, M. D., and Hortobagyi, G. N. Cancer. 88(9):2054-2060, 2000 May 1.

Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy.
Gregory, R. K.; Powles, T. J.; Salter, J.; Chang, J. C.; Ashley, S., and Dowsett, M. (Reprint available from: Gregory RK Royal Marsden Hosp, Dept Med, Breast Unit Downs Rd Sutton SM2 5PT Surrey England).. Breast Cancer Research & Treatment. 59(2):171-175, 2000 Jan.

High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study
Elkhuizen, P. H. M.; van Slooten, H. J.; Clahsen, P. C.; Hermans, J.; van de Velde, C. J. H.; van den Broek LCJM, and van de Vijver, M. J.. Journal of Clinical Oncology. 18(5):1075-1083, 2000 Mar.

Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial.
Broet, P.; Scholl, S. M.; de la Rochefordiere, A.; Fourquet, A.; Moreau, T.; De Rycke Y; Asselain, B., and Pouillart, P.. Breast Cancer Research & Treatment. 58(2):151-156, 1999 Nov.

Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Breslin, T. M.; Cohen, L.; Sahin, A.; Fleming, J. B.; Kuerer, H. M.; Newman, L. A.; Delpassand, E. S.; House, R.; Ames, F. C.; Feig, B. W.; Ross, M. I.; Singletary, S. E.; Buzdar, A. U.; Hortobagyi, G. N., and Hunt, K. K. Journal of Clinical Oncology. 18(20):3480-3486, 2000 Oct 15.

Value of estrogenic recruitment before chemotherapy: First randomized trial in primary breast cancer.
Bontenbal, M.; van Putten, W. L. J.; Burghouts, J. T. M.; Baggen, M. G. A.; Ras, G. J.; Stiegelis, W. F.; Beudeker, M.; Janssen, J. T. P.; Braun, J. J.; van der Linden, G. H. M.; van, d. e. r. Velden PC; van Geel, A. N.; Helle, P.; Leisink, M.; Foekens, J. A., and Klijn, J. G. M. Journal of Clinical Oncology. 18(4):734-742, 2000 Feb.

Oral bisphosphonates - A review of clinical use in patients with bone metastases [Review].
Major, P. P.; Lipton, A.; Berenson, J., and Hortobagyi, G. Cancer. 88(1):6-14, 2000 Jan 1.

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Pierga, J. Y.; Mouret, E.; Dieras, V.; Laurence, V.; Beuzeboc, P.; Dorval, T.; Palangie, T.; Jouve, M.; Vincent-Salomon, A.; Scholl, S.; Extra, J. M.; Asselain, B., and Pouillart, P. (Reprint available from: Pierga JY Inst Curie, Dept Med Oncol 26 Rue Ulm F-75248 Paris 05 France).. British Journal of Cancer. 83(11):1480-1487, 2000 Dec.

Relation between appropriateness of primary therapy for early-stage breast carcinoma and increased use of breast-conserving surgery.
Nattinger, A. B.; Hoffmann, R. G.; Kneusel, R. T., and Schapira, M. M. Lancet. 356(9236):1148-1153, 2000 Sep 30.

Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer.
Meric, F.; Mirza, N. Q.; Buzdar, A. U.; Hunt, K. K.; Ames, F. C.; Ross, M. I.; Pollock, R. E.; Newman, L. A.; Feig, B. W.; Strom, E. A.; Buchholz, T. A.; McNeese, M. D.; Hortobagyi, G. N., and Singletary, S. E.. Annals of Surgical Oncology. 7(6):435-440, 2000 Jul

High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin.
Ezzat, A. A.; Ibrahim, E. M.; Ajarim, D. S.; Rahal, M. M.; Raja, M. A.; Stuart, R. K.; Tulbah, A. M.; Kandil, A.; Al-Malik, O. A., and Bazarbashi, S. M.. Breast Cancer Research & Treatment. 62(3):237-244, 2000 Aug.

Inflammatory breast cancer survival: The role of obesity and menopausal status at diagnosis. Chang, S.; Alderfer, J. R.; Asmar, L., and Buzdar, A. U. (Reprint available from: Chang S Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol Box 189,1515 Holcombe Blvd Houston, TX 77030 USA). Breast Cancer Research & Treatment. 64(2):157-163, 2000 Nov.

Inflammatory breast carcinoma: Pathological or clinical entity?
Amparo, R. S.; Angel, C. D. M.; Ana, L. H.; Antonio, L. C.; Vicente, M. S.; Carlos, F. M., and Vicente, G. P (Reprint available from: Amparo RS Profesor Beltran Baguena 19 Valencia 46009 Spain). Breast Cancer Research & Treatment. 64(3):269-273, 2000 Dec.

Top of Page